본문 바로가기

Pipeline

  • home
  • R&D
  • Pipeline

Pipeline

이 표는 수집하는 개인정보 항목 및 수집방법, 개인정보의 수집목적 및 이용목적, 개인정보의 공유 및 제공, 수집한 개인정보 처리 위탁, 수집한 개인정보의 보유 및 이용기간, 개인정보 파기절차 및 방법, 이용자 및 법정대리인의 권리와 그 행사방법, 쿠키의 운영과 활용(자동수집장치 설치, 운영, 거부에 관한 사항), 개인정보 보호를 위한 이용자의 주의사항, 개인정보 관리 책임자, 부칙 구성되어 있습니다.
Therapeutic Area Project Code Target Indication Development Stage note
Lead NME Clinical NDA Product
Liver Disease ID119031166 NASH
FXR agonist
ID119050134 Hepatic cirrhosis
ATX inhibitor
CNS lasmiditan Migraine
5-HT1F agonist
License-in(from Eli Lilly)
ID119040338 Parkinson’s Disease
ID119040338
Collaboration (with iLeadBMS)
Oncology venadaparib Breast Cancer
PARP inhibitor
Developement by subsidiary(idience)
ID11902 Solid Tumor
A2a/A2b antagonist
Collaboration (with iLeadBMS)
ID119160021 Breast Cancer
4th Antiandrogen
Developement by subsidiary(idience)
Metabolic Disease IDG16177 Type-2 Diabetes
GPR40 agonist
ID110521156 Type-2 Diabetes
GLP-1R agonist
Ophthalmology IDB0062 Wet AMD
Anti-VEGF-A/NRP1
ID110410395 Dry Eye Disease
CFTR activator
Collaboration (with YUHS)
ID11901GL Glaucoma
PKG activator
Respiratory Disease ID119010023 Respiratory diseases
PKG activator
Collaboration (with iLeadBMS)
Gastrointestinal Disease ID120040002 GERD
PCAB
ico_exit

Liver Disease

ID119031166

• A potent non-steroidal FXR agonist to treat NASH:
 - Mechanism of action that inhibits the synthesis of bile acid
 - Strong activity and selectivity demonstrated in nonclinical studies
 - Significantly reduced NAFLD Activity score and fibrosis in animal models of NASH
 - Regulated direct FXR target genes in a dose-dependent manner in vivo
 - Not importantly altered plasma level of ALT/AST and LDL-C at the effective dose
• IND approval

NASH : NonAlcoholic SteatoHepatitis, NAFLD : NonAlcoholic Fatty Liver Disease,
FXR : Farnesoid X Receptor, ALT : Alanine aminotransferase,
AST : Aspartate aminotransferase, LDL-C : Low-Density Lipoprotein Cholesterol

ico_exit

CNS

LASMIDITAN

• Migraine therapy with an innovative mechanism of action with no restrictions on use in
    cardiovascular disease patients
 - The first and only Ditan drug approved by the FDA with a different mechanism from triptans
    (serotonin 1B receptor agonists) and NSAIDs, which have been used as migraine treatments.
 - Overcoming the limitations of existing triptans (limited use in cardiovascular patients) by
     exhibiting 470-fold or more affinity for serotonin 1F receptors compared to serotonin 1B and
     1D receptors associated with vasoconstriction
• NDA approval by MFDS on May 2022

NSAIDs : Non-steroidal anti-inflammatory drugs

ico_exit

Metabolic Disease

IDG16177

• A GPR40 agonist to treat type 2 diabetes mellitus
 - High oral absolute bioavailability in pre-clinical species
 - A defined MoA, activating β-arrestin2 recruitment as well as Gq-dependent pathway
 - Glucose-dependent insulin secretion & free of hypoglycemic risk
 - Superior to fasiglifam in glucose reduction in normal and diabetic rat studies
 - Potentially no risk of DILI (drug-induced liver injury)
Phase 1 has started in Germany in July 2021 to evaluate safety and pharmacokinetics
    (NCT04982705)
Phase 1 (SAD, MAD) completed in August 2022

ico_exit

Metabolic Disease

ID110521156

•A small-molecule glucagon-like peptide (GLP)-1 receptor agonist to treat type 2 diabetes
 - Being developed as an oral drug
 - Overcame the disadvantages of existing injection drugs (improved safety profile and
    patient adherence)
 - Potential of expansion to various indications including NASH and Obesity
• IND submission expected in Q1 2023

GLP-1 : Glucagon-like peptide-1, NASH : NonAlcoholic SteatoHepatitis

ico_exit

Ophthalmology

IDB0062

• A dual-targeting antibody fragment drug for wet AMD
 - A dual target antibody fragment in which a tissue penetrating peptide targeting NRP1 is linked to the anti-VEGFA antibody fragment
 - Stronger efficacy by inhibition of multiple pathological growth factors in ocular angiogenic diseases
 - Expected extended dosing interval based on improved ocular PK profile(Once every 2 or 3 months) 
 - Possibility on less invasive treatment through tissue-penetrating peptides
• Possibility of absence of ocular/systemic side effects through toxicological benefit​
• Accelerating CMC development with Global CDMO

ico_exit

Ophthalmology

ID110410395

• First-in-class small molecule CFTR activator to treat dry eye disease
 - A novel mode of action in which DED symptoms are improved by restoration of tear film homeostasis through tear secretion and anti-inflammatory action.
 - targets to improve both signs and symptoms with favorable tolerability profile and
    simplified dosing
• IND submission expected in Q4 2022

CFTR : Cystic Fibrosis Transmembrane Conductance Regulator

ico_exit

Ophthalmology

ID11901GL

• A nitric oxide-donating PDE5 inhibitor for Glaucoma
 - Metabolized in the body to release nitric oxide and at the same time inhibits PDE5/6 to
     increase PKG (protein kinase G) activity
 - Activates PKG by increasing the amount of cGMP by inhibiting the degradation of cGMP
 - Activated PKG relaxes smooth muscle and increases blood flow

cGMP : Cyclic Guanosine MonoPhosphate

ico_exit

Gastrointestinal Disease

ID120040002

A novel Potassium-Competitive Acid Blocker (P-CAB) to treat gastric acid related diseases:
 - Strong inhibition of proton pump (H+/K+ ATPase)
 - High retention time in stomach for effective proton pump inhibition
 - Inhibition of basal gastric acid secretion and fast-onset of efficacy in vivo
IND submission expected in Q3 2022

ico_exit

Respiratory Disease

ID119010023

• A nitric oxide-donating PDE5 inhibitor for ARDS, PAH
 - Highly selective and potent in vitro activity
 - Efficacy shown in an acute lung injury mouse model
• in vivo efficacy study, formulation, PK analysis are on-going
• IND submission expected in 1Q 2023

ARDS : Acute Respiratory Distress Syndrome, PDE5 : PhosphoDiEsterase 5

* HBV polymerase inhibitor : Regulatory approval in Korea in May 2017 The 28th domestic new drug

* GPR40 agonist : Clinical Trial Application (CTA) approval in June 2021 in Germany

* YUHS : Yunsei University Health System

TOP